Newcastle researchers have revealed the first treatment to target the underlying cause of a rare kidney condition called "C3G ...

Cystatin C is an emerging biomarker that enhances kidney function assessment accuracy, particularly in hospitalized patients ...

Newcastle researchers have revealed the first treatment to target the underlying cause of a rare kidney condition called “C3G ...

Changes in kidney function are better reflected by creatinine concentration than BUN. The latter can be affected by non-renal ...

APLS is expanding SYFOVRE's potential with a phase 2 study combining it with siRNA APLS-3007, aiming to enhance efficacy in ...

New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL ...

As father and son, we represent two connected fields of medicine. Dr. Ahsan, a Professor of Cardiology, has spent decades ...

Explore practical implications of new research in nephrotic syndrome, from renal biopsy and genetic testing to managing ...

A RED flag sign in your pee could mean you have a 25 per cent higher risk of dementia, scientists say. Having high levels of the protein albumin in your pee could mean you’re at increased ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Climb Bio (CLYM) announced results from a completed nonhuman primate study comparing CLYM116 to sibeprenlimab, a first-generation anti-APRIL ...

In June 2024, Nkarta announced the initiation of Ntrust-I, a multi-center clinical trial of NKX019 in lupus nephritis, with ...